Malaria is a devastating disease that results in 460,000 deaths annually. Our laboratory is contributing to the global effort to develop novel small molecule therapies to treat and eliminate malaria.
Our team is currently optimising several small molecule classes identified from phenotypic screening of the malaria parasite. The antimalarial classes exert differential activity against multiple stages of the parasite’s lifecycle and therefore have potential as a prophylactic, a curative therapy or being used to eliminate malaria from endemic regions.
We are also employing chemical biology and genetic techniques to identify the mechanism of action of the small molecule classes under development.
Team members: Trent Ashton, William Nguyen, Madeline Dans, Kyle Awalt, Wenyin Su, Petar Calic, Mahta Mansouri.
Collaborators: Alan Cowman, Kym Lowes, external collaborators and industry partners